Eric F. Morand

21.3k total citations · 6 hit papers
346 papers, 12.6k citations indexed

About

Eric F. Morand is a scholar working on Immunology, Rheumatology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eric F. Morand has authored 346 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 196 papers in Immunology, 183 papers in Rheumatology and 73 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eric F. Morand's work include Systemic Lupus Erythematosus Research (172 papers), Monoclonal and Polyclonal Antibodies Research (73 papers) and Macrophage Migration Inhibitory Factor (59 papers). Eric F. Morand is often cited by papers focused on Systemic Lupus Erythematosus Research (172 papers), Monoclonal and Polyclonal Antibodies Research (73 papers) and Macrophage Migration Inhibitory Factor (59 papers). Eric F. Morand collaborates with scholars based in Australia, United States and United Kingdom. Eric F. Morand's co-authors include Michelle Leech, Leilani L. Santos, Alberta Hoi, Fabien B. Vincent, Yuan Yang, Fabienne Mackay, Raj Tummala, Richard Furie, Paul Hutchinson and Ian N Bruce and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Eric F. Morand

332 papers receiving 12.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

2019 778 citations Eric F. Morand, Richard Furie et al. profile →
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

2015 441 citations Chak Sing Lau, Worawit Louthrenoo et al. Annals of the Rheumatic Diseases profile →
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

2019 289 citations Richard Furie, Eric F. Morand et al. profile →
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Eric F. Morand, Joan T. Merrill et al. Arthritis & Rheumatology profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

2023 89 citations Ian N Bruce, Yoshiya Tanaka et al. profile →
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2023 79 citations Eric F. Morand, Ronald van Vollenhoven et al. profile →

Peers

Countries citing papers authored by Eric F. Morand

Since Specialization

Citations

This map shows the geographic impact of Eric F. Morand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric F. Morand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric F. Morand more than expected).

Fields of papers citing papers by Eric F. Morand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric F. Morand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric F. Morand. The network helps show where Eric F. Morand may publish in the future.

Co-authorship network of co-authors of Eric F. Morand

This figure shows the co-authorship network connecting the top 25 collaborators of Eric F. Morand. A scholar is included among the top collaborators of Eric F. Morand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric F. Morand. Eric F. Morand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL 2024 ·Annals of the Rheumatic Diseases ·Ronald van Vollenhoven, Joseph F. Merola, (unknown), Piotr Leszczyński, M C Pike, Shirley A. Pomponi, (unknown), (unknown), (unknown), (unknown), (unknown), Eric F. Morand	0
2	LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis 2024 ·SHILAP Revista de lepidopterología ·Ronald van Vollenhoven, Eric F. Morand, Richard Furie, Kenneth Kalunian, Raj Tummala, Gabriel Abreu, Hussein Al‐Mossawi, Catharina Lindholm	2
3	OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB 2023 ·Annals of the Rheumatic Diseases ·Eric F. Morand, Ronald van Vollenhoven, Richard Furie, Kenneth Kalunian, (unknown), Gabriel Abreu, (unknown), Hussein Al‐Mossawi	5
4	Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort 2023 ·Arthritis & Rheumatology ·Olivia Solomon, Cristina Lanata, (unknown), Joanne Nititham, Kimberly E. Taylor, Sharon A. Chung, Jinoos Yazdany, Maria Dall’Era, Bernardo A. Pons‐Estel, Teresa Tusié‐Luna, Betty P. Tsao, Eric F. Morand, Marta E. Alarcón‐Riquelme, Lisa F. Barcellos, Lindsey A. Criswell	1
5	AB0144 PHARMACOLOGICAL CHARACTERIZATION OF GLPG3667, A SELECTIVE TYK2 INHIBITOR, SUPPORTS DEVELOPMENT IN DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS 2023 ·Annals of the Rheumatic Diseases ·(unknown), Eric F. Morand, Roland Blanqué, Kenji F. Shoji, (unknown), Florence Marsais, Laetitia Furio, Máikel L. Colli, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), A. Van de Water, (unknown), Stephen E. Alves, (unknown), (unknown), René Galien	1
6	1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW) 2022 ·SHILAP Revista de lepidopterología ·Eric F. Morand, Victoria P. Werth, Andrew T. Bender, (unknown), (unknown), Bharat Vaidyanathan, (unknown), Melinda Przetak, Flavie Moreau, (unknown), Sanjeev Roy, David R. Pearson	0
7	Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials 2022 ·Lara D. Veeken ·Ian N Bruce, Ronald van Vollenhoven, Eric F. Morand, Richard Furie, Susan Manzi, William B. White, Gabriel Abreu, Raj Tummala	20
8	Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia 2022 ·Cells ·(unknown), (unknown), (unknown), (unknown), Leonardo Camilo de Oliveira, Juliana P. Vago, (unknown), Marina Machado, (unknown), Celso Martins Queiroz‐Junior, Eric F. Morand, Stefano Bruscoli, Carlo Riccardi, Mauro Martins Teixeira, Luciana P. Tavares, Lirlândia P. Sousa	8
9	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials 2022 ·Annals of the Rheumatic Diseases ·Ian N Bruce, Richard Furie, Eric F. Morand, Susan Manzi, Yoshiya Tanaka, Kenneth Kalunian, Joan T. Merrill, (unknown), (unknown), C. Kleoudis, (unknown), Micki Hultquist, Raj Tummala	26
10	POS0774 ANTI-Sm AUTOANTIBODIES IDENTIFY A PHENOTYPE OF SEVERE SLE WITH AN ASSOCIATED SERUM BIOMARKER PROFILE 2022 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), (unknown), (unknown), (unknown), Artemis Papadaki, (unknown), (unknown), (unknown), Eric F. Morand	1
11	Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides 2021 ·Nucleic Acids Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Kim A. Lennox, Julia I. Ellyard, (unknown), Tomalika R. Ullah, Gina D. Kusuma, Geneviève Pépin, Hongmei Li, Jaclyn S. Pearson, Jonathan Ferrand, Rebecca Lim, Rakesh N. Veedu, Eric F. Morand, Carola G. Vinuesa, Mark A. Behlke, Michael P. Gantier	17
12	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort 2021 ·Clinical Rheumatology ·Yanjie Hao, Shereen Oon, Lanlan Ji, Dai Gao, Yong Fan, Yan Geng, Xiaohui Zhang, Guangtao Li, Eric F. Morand, Mandana Nikpour, (unknown)	15
13	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation 2020 ·Cell Reports ·Isabella Y. Kong, (unknown), Amanda Light, Izabela Todorovski, Sarah A. Jones, Eric F. Morand, Deborah A. Knight, (unknown), Simon J. Hogg, Hendrik Falk, Brendon J. Monahan, Paul A. Stupple, Ian P. Street, Susanne Heinzel, Philippe Bouillet, Ricky W. Johnstone, Philip D. Hodgkin, Stephin J. Vervoort, Edwin D. Hawkins	5
14	Necrotic cell death increases the release of macrophage migration inhibitory factor by monocytes/macrophages 2020 ·Immunology and Cell Biology ·Wendy Dankers, Md Abul Hasnat, (unknown), (unknown), Jacinta P. W. Lee, (unknown), Michael P. Gantier, Sarah A. Jones, Eric F. Morand, Jacqueline K. Flynn, James Harris	14
15	Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus 2019 ·Lupus ·Rangi Kandane‐Rathnayake, (unknown), Worawit Louthrenoo, (unknown), (unknown), Aisha Lateef, Vera Golder, Sargunan Sockalingam, (unknown), Leonid Zamora, Laniyati Hamijoyo, Yasuhiro Katsumata, Masayoshi Harigai, Madelynn Chan, Sean O’Neill, Fiona Goldblatt, Chak Sing Lau, Alberta Hoi, Mandana Nikpour, Eric F. Morand	10
16	Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus 2019 ·Clinical & Translational Immunology ·William A. Figgett, (unknown), Milica Ng, Monther Alhamdoosh, Eugene Maraskovsky, Nicholas J. Wilson, Alberta Hoi, Eric F. Morand, Fabienne Mackay	32
17	Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis 2015 ·Cytokine ·Ran Gu, Leilani L. Santos, Devi Ngo, Huapeng Fan, (unknown), Günter Fingerle‐Rowson, Richard Bucala, Jiake Xu, Julian M.W. Quinn, Eric F. Morand	36
18	Disseminated Enteroviral Infection Associated with Obinutuzumab 2015 ·Emerging infectious diseases ·Claire Dendle, Michael Gilbertson, Tony M. Korman, Vera Golder, Eric F. Morand, Stephen Opat	16
19	Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2 2006 ·The Journal of Immunology ·Julia L. Gregory, Eric F. Morand, Sonja J. McKeown, (unknown), Pamela Hall, Yuan Yang, Shaun R. McColl, Michael J. Hickey	178
20	Regulation of apoptosis/proliferation and p53 by MIF in RA fibroblast-like synoviocytes 2001 ·Queensland's institutional digital repository (The University of Queensland) ·(unknown), Yao‐Hsu Yang, Paul Hutchinson, Ernst J. Wolvetang, Michelle Leech, Eric F. Morand	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact